Independent urology practices head into 2027 facing a conversion factor cut, prior authorization hurdles, and Part B drug price negotiation, according to Gary Kirsh, MD.
Justin B. Ziemba, MD, discusses clinical factors that help identify patients at increased risk for kidney stone recurrence and guide metabolic evaluation.
Adam Sharp, PhD, BM, MRCP, BSc, discusses preliminary safety and efficacy findings from a phase 1/2 study of gedatolisib plus darolutamide in patients with mCRPC.
The phase 1/2 ARGATE-001 trial will assess the safety, tolerability, and preliminary efficacy of EIK1006 in patients with metastatic androgen pathway modulation-resistant prostate cancer.
Expert urologists argue that testosterone is an underused biomarker of men’s health, and review how TRAVERSE resolved longstanding cardiovascular safety concerns.
Muhammed A. Moukhtar Hammad, MBBCh, MSc, discusses real-world trends in baseline erectile dysfunction treatment across AUA sections before minimally invasive BPH procedures.